Yahoo Search Búsqueda en la Web

Entrar

Resultado de búsqueda

  1. www.casadellibro.com › libro-keynote-advanced-with-the-spark-platformKEYNOTE ADVANCED WITH THE SPARK PLATFORM - Casa del Libro

    28 de jun. de 2024 · Ficha técnica. Editorial: INDEPENDENTLY PUBLISHED. ISBN: 9798214334349. Idioma: INGLÉS. Encuadernación: Tapa blanda. Fecha de lanzamiento: 28/06/2024. Año de edición: 2024. ¿Has leído KEYNOTE ADVANCED WITH THE SPARK PLATFORM? Compra el libro KEYNOTE ADVANCED WITH THE SPARK PLATFORM con ISBN 9798214334349 al mejor precio en Casa del Libro.

  2. paris.aesop-planning.eu › full-weekFULL WEEK

    2 de jul. de 2024 · Keynote IV (Closing Session) 27SG: Emile Boutmy (retransmitted in: Jacques Chapsal, Albert Sorel, Leroy Beaulieu, Eugène d\'Eichtal) 11.15 - 12.30. 11.30 11.45 12.00 12.15 Friday 12 July Keynote IV (Closing Session) 11.15 - 12.30 Monday 8 July Tuesday 9 July Wednesday 10 July ...

  3. www.nature.com › articles › s41568/024/00699-2Exploiting temporal aspects of cancer immunotherapy - Nature

    17 de jun. de 2024 · An analysis of the KEYNOTE-001 trial has shown that patients with NSCLC who had received radiotherapy as a previous line of therapy before anti-PD1 experienced improved survival compared with...

  4. www.mdpi.com › 2072/6694/16-13 › 2421Cancers | Free Full-Text | Breast Cancer Patient’s ... -...

    30 de jun. de 2024 · Neoadjuvant chemotherapy in breast cancer facilitates breast and axillary surgery and offers significant prognostic value. We present a retrospective cohort of 482 stage II and III breast cancer patients treated with neoadjuvant chemotherapy based on anthracycline and taxans, plus antiHER2 in HER2-positive cases.

  5. link.springer.com › article › 10Impact of Presenting Stage on Overall Survival in Patients...

    13 de jun. de 2024 · For operable triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NAC), clinical prognostication and postoperative decision-making relies exclusively on whether a pathologic complete response (pCR) is achieved or not.

  6. www.urotoday.com › video-lectures › asco-2024Understanding KEYNOTE-564: Pembrolizumab’s Role and Post-Adjuvant...

    26 de jun. de 2024 · Zach Klaassen engages with Talal El Zarif and Karl Semaan to discuss the results of the KEYNOTE-564 trial on adjuvant immunotherapy for renal cell carcinoma (RCC). The conversation emphasizes the landmark approval of pembrolizumab as adjuvant therapy in early-stage RCC, highlighting a significant shift in treatment paradigms where ...

  7. trials.cancervic.org.au › detailsKEYNOTEB10 - Victorian Cancer Trials Link

    11 de jun. de 2024 · A Phase 4, Single-arm, Open-label Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Efficacy and Safety of MK-3475 Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE B10).